HolderBook

Broadfin Capital, LLC

Reported holdings as of Q4 2019, from 5 quarterly filings.

This filer last reported in Q4 2019; the most recent quarter on file across all filers is Q2 2026. Firms that restructure stop filing under one CIK and start under another, so a successor entity may hold these positions now under a similar name.

CIK
1511901
Reported value
$746.8M
Positions
38
Top 10 weight
66.7%
Filed
2020-02-14
Days after quarter end
45

Holdings

SecurityTickerValue SharesWeightWeight change Held Change
STATE STR SPDR S&P 500 ETF T OPTSPY$141.6Moptions only18.96%-5.18pp2qOPTIONS
ISHARES TR OPTIWM$132.5Moptions only17.75%-newOPTIONS
BIOHAVEN PHARMACTL HLDG CO L OPTBHVNXXXX$54.9M409,3387.36%-0.61pp5q-23.1%-$16.5M
SPDR SERIES TRUST OPTXBI$33.3Moptions only4.46%-5.41pp2qOPTIONS
BIODELIVERY SCIENCES INTL INBDSI$27.2M4,300,0663.64%+0.29pp5qHELD
ALKERMES PLC OPTALKS$25.2M1,033,5003.37%+2.47pp2q+315.1%+$19.1M
VIEWRAY INCVRAYQ$23.5M5,574,3663.15%+1.54pp5q+85.7%+$10.9M
AMARIN CORP PLCAMRNXXXX$22.5M1,049,2443.01%-1.39pp3q-33.1%-$11.1M
QUOTIENT LTDQTNT$19.0M1,994,1832.54%+1.66pp5q+225.1%+$13.1M
EIGER BIOPHARMACEUTICALS INCEIGR$18.4M1,236,3682.47%-0.12pp5q-9.6%-$2.0M
STAAR SURGICAL COSTAA$16.3M462,1182.18%-newNEW
INTERSECT ENT INCXENT$15.7M631,0232.10%-0.35pp2q-19.0%-$3.7M
PROGENICS PHARMACEUTICALS INPGNX$15.6M3,060,9232.09%+0.61pp2q+93.2%+$7.5M
NANOSTRING TECHNOLOGIES INCNSTGQ$15.5M555,6002.07%+1.63pp5q+401.4%+$12.4M
IOVANCE BIOTHERAPEUTICS INCIOVA$14.8M533,3011.98%-1.83pp5q-52.9%-$16.5M
DERMIRA INCDERM$13.6M896,3341.82%+1.13pp2q+54.6%+$4.8M
RECRO PHARMA INCSCTL$13.2M721,0731.77%-0.25pp5q-27.0%-$4.9M
LANTHEUS HLDGS INCLNTH$12.7M617,9531.70%-newNEW
VAPOTHERM INCVAPO$12.2M1,003,0991.63%-newNEW
SIENTRA INCSIENXXXX$11.5M1,286,9871.54%-0.86pp3q-35.7%-$6.4M
VERICEL CORPVCEL$10.8M620,1991.44%+0.78pp5q+161.6%+$6.7M
LA JOLLA PHARMACEUTICAL COLJPC$10.6M2,688,0681.41%+1.12pp5q+1378.2%+$9.8M
ALEXION PHARMACEUTICALS INCALXN$9.0M83,1001.20%-newNEW
SOL GEL TECHNOLOGIESSLGL$8.9M521,8191.20%+0.26pp5q-7.4%-$711.4K
RELMADA THERAPEUTICS INCRLMD$8.6M220,7241.15%-newNEW
AURINIA PHARMACEUTICALS INCAUPH$8.1M400,0001.09%-newNEW
AVADEL PHARMACEUTICALS PLCAVDLXXXX$7.8M1,029,0121.04%-1.35pp5q-66.8%-$15.7M
EXICURE INCXCUR$7.7M2,707,8511.04%-0.04pp2q+17.1%+$1.1M
ZOGENIX INCZGNX$7.0M134,9370.94%-0.08pp5q-2.2%-$161.6K
ICU MED INCICUI$5.6M30,0000.75%-0.13pp2qHELD
LUMINEX CORP DELLMNX$4.8M207,5530.64%-newNEW
STRATA SKIN SCIENCES INCSSKN$3.8M1,839,3720.51%-0.65pp5q-36.9%-$2.2M
ANAPTYSBIO INCANAB$3.6M221,6000.48%-newNEW
ACLARIS THERAPEUTICS INCACRS$3.6M1,888,0390.48%+0.15pp2q+16.5%+$506.5K
MYLAN N VMYL$3.0M150,0000.40%-newNEW
HERON THERAPEUTICS INCHRTX$2.1M89,7300.28%-0.40pp5q-8.7%-$199.9K
SCYNEXIS INCSCYX$1.8M2,000,0000.24%-newNEW
PALATIN TECHNOLOGIES INCPTN$819.0K1,047,3100.11%-0.07pp2qHELD

By sector

Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.

Funds & ETFs 19.0%Biotech & Pharma 16.4%Medical Devices 2.9%Not classified 61.7%
 
SectorValueShare
Funds & ETFs$141.6M19.0%
Biotech & Pharma$122.3M16.4%
Medical Devices$21.9M2.9%
Not classified$461.0M61.7%

Quarter by quarter

QuarterValuePositions NewAddedTrimmed ExitedTop 10 Days to file
Q4 2019$746.8M381110121566.7%45
Q3 2019$540.9M4214619764.4%45
Q2 2019$459.6M3556211161.5%45
Q1 2019$484.3M413924954.9%45
Q4 2018$760.5M47000064.6%45

Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.

Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.

Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.